Vericel Corporation Stock News

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Mason Carrico - Stephens Operator Thank you for standing by.

Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Confe...

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025.

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results an...

Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest sign...

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:

Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffr...